Jennifer Kayden Lee - 07 Aug 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
EVP, Head of North America
Signature
/s/ Hunter Smith, Attorney-in-Fact for Jennifer Lee
Issuer symbol
RYTM
Transactions as of
07 Aug 2023
Net transactions value
-$243,612
Form type
4
Filing time
09 Aug 2023, 16:30:20 UTC
Previous filing
14 Feb 2023
Next filing
07 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise $58,419 +8,591 +145% $6.80 14,517 07 Aug 2023 Direct F1
transaction RYTM Common Stock Sale $271,347 -11,223 -77% $24.18 3,294 07 Aug 2023 Direct F2
transaction RYTM Common Stock Options Exercise $11,682 +1,718 +52% $6.80 5,012 09 Aug 2023 Direct
transaction RYTM Common Stock Sale $42,366 -1,718 -34% $24.66 3,294 09 Aug 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Option (Right to Buy) Options Exercise $0 -8,591 -10% $0.000000 73,909 07 Aug 2023 Common Stock 8,591 $6.80 Direct F3
transaction RYTM Stock Option (Right to Buy) Options Exercise $0 -1,718 -2.3% $0.000000 72,191 09 Aug 2023 Common Stock 1,718 $6.80 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 986 shares acquired under Issuer's Employee Stock Purchase Plan on February 28, 2023.
F2 The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023.
F3 The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.